Pancreatic ductal adenocarcinoma is a disease of extremely poor prognosis for which there are no reliable markers of asymptomatic disease. To identify pancreatic cancer biomarkers, we focused on a genomic interval proximal to the most common fragile site in the human genome, chromosome 3p12, which undergoes smoking-related breakage, loss of heterozygosity and homozygous deletion as an early event in many epithelial tumors, including pancreatic cancers. ELISA assays for TFPI/TNC resulted in a combined AUC of 0.88 and, with addition of CA 19-9, a combined AUC for the three gene panel (TNC/TFPI/CA19-9) was 0.99 with 100% specificity at 90% sensitivity and 97.22% sensitivity at 90% specificity. Validation studies using TFPI only in a blinded sample set increased the performance of CA19-9 alone from an AUC of 0.84 to 0.94 with the two gene panel. Results identify a novel 3p pathway associated migration signature and plasma biomarker panel that has utility for discrimination of pancreatic cancer from normal controls and promise for clinical application.
INTRODUCTION
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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Suppression Subtractive Hybridization (SSH) Library
The SSH library was previously constructed using as starting materials for library construction microcell hybrids formed by the introduction of defined fragments of a normal chromosome 3p
into a renal cell carcinoma cell line and subsequent assay of those microcell hybrids for tumor formation in athymic nude mice (10) . Methods utilized for library construction have been previously published and are shown schematically in Fig. 1A . We hypothesized that the resultant differentially expressed cDNAs obtained from the SSH library should represent genes up or downregulated by the introduction of the NRC-1 tumor suppressor locus and could represent genes in a functional chromosome 3p12 tumor suppression pathway and conversely, identification of this pathway could elucidate how loss of this genomic region and deregulation of this pathway could be involved in the early stages of pancreatic cancer. We furthermore hypothesized that characterization of this library could define genetic networks in pancreatic cancer that could serve as a source for biomarkers for early detection. .
Bioinformatic analyses
To generate the highest quality expression data, the PDNN (positional-dependent-nearestneighbor) model was chosen to account for existing probe variation in specific binding with the labeled target material (11) . Existing algorithms, such as MAS 5.0, do not take into account probe specific variation in binding efficiency and can result in variation in probe signal that vary over two orders of magnitude within a single probeset. Probe normalization and summarization was performed using the PerfectMatch software suite utilizing the PDNN algorithm (http://bioinformatics.mdanderson.org/software.html). For each probeset, the software outputs both the natural logarithm transformed expression level and correlation coefficient between the observed and modeled data. Data was filtered to identify genes exhibiting greater than or equal to 2 fold changes in gene expression.
Network and gene ontology analysis
Selected genes were investigated for network and gene functional interrelation by Ingenuity
Pathways Analysis (IPA) software (Ingenuity Systems, www.ingenuity.com) (12) . IPA scans the set of input genes to identify networks by using Ingenuity Pathways Knowledge Base for interactions between identified 'Focus Genes', in our case, the common genes identified from our pathways approach and known and hypothetical interacting genes stored in the knowledge base in IPA software, to generate a set of networks with a maximum network size of 35 genes/proteins.
Networks are displayed graphically as genes/gene products ('nodes') and the biological relationships between the nodes ('edges'). All edges are from canonical information stored in the Ingenuity Pathways Knowledge Base. In addition, IPA computes a score for each network according to the fit of the user's set of significant genes. profiles across platforms to identify differentially expressed sequences which we subsequently filtered by bioinformatic analyses to identify those genes with expression differences of ≥ 2 fold.
Supplementary Table S2 RNA from matched tumor/adjacent normal samples (8 paired samples) was utilized to interrogate the array and resultant bioinformatic analysis performed to identify differentially expressed sequences across all three platforms. Bioinformatic analysis involved the stratification of the data set by selecting only those genes from the 82 gene list that were significantly differentially expressed across all three expression platforms resulting in a 7 gene set, p<0.05) ( Table 1 ). The seven gene panel [WWTR1 (13, 14) , TGFBI (15, 16) , TFPI (17,18), CDC42BPA (19, 20) , L1CAM, (21, 22) , TNC (23, 24) and SEL1L (25, 26) ] demonstrated at least greater than or equal to 2 fold difference in gene expression and consistently remained as top candidates that were differentially expressed across three platforms. One gene, SEL1L, was significantly downregulated in 8/8
tumors as compared with normal adjacent tissue, while the other 6 genes were up-regulated.
Importantly, 5 out of 7 genes had also been previously published as being differentially Figure S1) . In contrast, SEL-1L was found to be significantly downregulated in pancreatic adenocarcinomas compared to the normal pancreas (Supplementary Figure S1) .
Furthermore, we also analyzed the expression of our panel in three different expression datasets obtained from microdissected pancreatic tumor/normal samples (28) (29) (30) . Importantly, although none of the 3 databases used listed all 7 genes as differentially expressed, subsets of each of the 7 gene panel were represented in these datasets as well ( Supplementary Figures S2 and S3) . Thus, insilico analyses has confirmed out studies using cross platform functional approaches although none of the previously published compendiums of expression profiles identified these genes as a panel or studied their potential as blood-based pancreatic cancer biomarkers. Thus, our functional approach identified a novel panel differentially expressed in multiple datasets which hitherto had not been studied for blood-based biomarker development.
Ingenuity Pathway Analysis Identifies a Single Network and Migration Signature for 3p
Pathway Genes. To determine the functional relationships among the seven genes confirmed by our functional genomic pathway studies, Ingenuity Pathway Analysis (IPA) was queried for known or hypothetical interactions among the seven genes in the panel as well as all other genes in the Ingenuity database. With the exception of WWTR1/TAZ which was not present in the IPA database, all the other 6 genes were used as focus genes for IPA. Unsupervised IPA network analysis identified a network of 35 genes that included all six focus genes and 29 additional genes (Score =16) ( Table 2 ). The interactive relationship between the genes in the network are shown in Fig.1B . Importantly, all 6 genes were classified into a single network related to cellular movement, cell morphology and cellular development ( Table 2) . Of the 6 genes, 5 also were a part of a network involving cell signaling and cell interaction (p=7.07E-06~3.07E-02) and cell movement (p=1.38E-04~3.51E-02). The extremely low probability of obtaining this number of Fig. 2D illustrates the ROC curve to compare the ability of plasma TFPI in distinguishing patients with pancreatic cancer versus normal subjects. The AUC for TFPI was 0.87 with a specificity was 63% given 90% sensitivity and a sensitivity of 64% given 90% specificity.
We next tested whether the combination of the two markers, TNC and TFPI, could increase sensitivity and specificity for discrimination between cancer and normal plasma samples. The combined AUC for both markers was 0.88 (Fig. 2E) . The combination of markers resulted in a specificity of 63% given 90% sensitivity and a sensitivity of 67% given 90% specificity. These combined results, then, suggest that the two gene panel identified through our functional genomic studies has high sensitivity and specificity to discriminate tumor and normal samples in the plasma and indicate that these genes are candidate blood-based biomarkers for pancreatic cancer.
The diagnostic potential of candidate biomarkers TNC and TFPI, relative to and in combination with CA19-9, the standard serum biomarker for pancreatic cancer, was determined. Results indicated that individual plasma CA 19-9 levels, presented in the form of a scatter plot (Fig. 2F) ,
were significantly different between pancreatic cancer patients versus normal screening controls in that the median plasma CA 19-9 levels was 173 U/ml in patients with pancreatic adenocarcinoma (n=36) as compared to levels in normal subjects (11.9) (n=19) (Student's t test, 
Copyright © 2010 American Association for Cancer Research P<0.00001; Mann-Whitney's U test, P <0.00001). Fig. 2G illustrates the ROC curve for CA 19-9, and the AUC was 0.93, with a specificity of 94.74% at 90% sensitivity and sensitivity of 91.67% at 90% specificity. Fig. 2H illustrates the ROC curve for CA 19-9 and TFPI combined, and the AUC was 0.99, with a specificity of 100% at 90% sensitivity and sensitivity of 97.22% at 90% specificity.
We next tested whether the combination of the two markers TNC and TFPI with CA 19-9 could further increase sensitivity and specificity for discrimination between cancer and normal plasma samples. The combined AUC for all the markers was 0.99 (Supplementary Figure S4) . The combination of markers resulted in a specificity of 100% given 90% sensitivity and a sensitivity of 97.22% given 90% specificity.
To further strengthen our findings and to validate our results in a different sample set, we tested TFPI levels by ELISA in plasma samples from normal and pancreatic adenocarcinoma patients collected at the University of Alabama (UAB), Birmingham. A description of the UAB sample set is given in Table 3 ). Since the addition of TNC did not add significantly to the sensitivity and specificity (Supplementary Figure S4) , we analyzed only TFPI levels in these samples. Fig. 3A depicts the individual plasma TFPI levels of normal and pancreatic cancer patients. Plasma TFPI levels of patients with pancreatic adenocarcinoma were significantly higher compared with normal subjects (Student's t test, P= 0.000014; Mann-Whitney's U test,
P=0
.0001), with the median plasma TFPI level of 45.7 ng/ml in pancreatic adeonocarcinoma patients (n=37) compared to normal subjects (25.6) (n=15). Fig. 3B illustrates the ROC curve to compare the ability of plasma TFPI in distinguishing patients with pancreatic cancer versus normal subjects. The AUC for TFPI was 0.87 with a specificity of 46.67% at 90% sensitivity and 70.27 % sensitivity at 90% specificity. Next we analyzed CA 19-9 by ELISA in these samples and results indicated that individual plasma CA 19-9 levels, presented in the form of a scatter plot (Fig. 3C) , were significantly different between pancreatic cancer patients versus normal screening controls in that the median plasma CA 19-9 levels was 171.2 U/ml in patients with pancreatic adenocarcinoma (n=37) as compared to levels in normal subjects (15.7) (n=15) (Student's t test, P=0.0000000400227;
Mann-Whitney's U test, P=0.0001). Fig. 3D illustrates the receiver operator characteristic (ROC) curve for CA 19-9, and the area under curve (AUC) was 0.84, with a specificity of 13.33% at 90% sensitivity and 75.68% sensitivity at 90% specificity. The combined AUC for TFPI and CA 19-9 was 0.94 (Fig. 3E ). The combination of markers resulted in a specificity of 86.67% at 90% sensitivity and 83.78% sensitivity at 90% specificity.
DISCUSSION
Attempts to identify pancreatic cancer biomarkers have failed to produce a single marker with the sensitivity and specificity necessary for population screening. We reasoned that a targeted strategy to identify differentially expressed genes related to the earliest cytogenetic aberrations might be more successful in developing such biomarkers because we would be able to focus on those aberrantly expressed genes, which may be involved in initiating the pathways that ultimately lead to tumorigenesis, invasion and metastasis. Using three different expression platforms, we identified a 7 gene set as being differentially expressed between pancreatic cancer and normal samples and from which we have validated a subset of markers for differential expression by ELISA assays. Our results indicate that we have been able to identify two relevant Our results also identify TFPI as a novel pancreatic plasma biomarker candidate. TFPI is a major inhibitor of the tissue factor pathway of blood coagulation in vivo. Plasma TFPI levels have been shown to increase significantly at the time of diagnosis compared to controls and reach near normal levels following surgical removal of pancreatic tumor (37) . Plasma TFPI has also been reported to be increased in acute pancreatitis compared to normal subjects (38) . Plasma levels of total TFPI has been found to be upregulated in a number of solid tumors involving colon, pancreas and stomach (39) . Recently, increased TFPI expression levels have also been reported in colon and breast tumor tissues (40) . Our study suggests that plasma TFPI levels may be a potential biomarker for pancreatic cancer and can also serve as a prognostic marker owing to its 19-9 in plasma can discriminate pancreatic adenocarcinoma patients from normal screening controls with better sensitivity and specificity than CA19-9 alone, at least in our pilot studies.
These results could have significance for the early screening of pancreatic cancer given that CA19-9 alone fails to have adequate predictive value. Since CA19-9 is typically a serum marker, these results would furthermore suggest that future analyses of the value of CA19-9 screening in plasma as well as its use in combination with TFPI are warranted to determine if the combined panel could result in a viable test for general population screening. 
Copyright © 2010 American Association for Cancer Research morphogenesis. In addition, other members of the 7 gene panel have also been documented to play a role in cell migration and early stages of pancreatic cancer, suggestive that this network may be critically deregulated in early pancreatic cancer. TNC has been shown to mediate proliferation and migration of astrocytes in a wound assay (41) . Tumor associated isoforms of TNC has been shown to promote breast cancer cell invasion and growth (42) . TNC signaling has been reported to play an important role in mammary tumor growth and metastasis and knockdown of TNC exhibited significant impairment in cell migration and anchorage-dependent cell proliferation in breast cancer cell line (43) . In addition TNC has also been shown to stimulate glioma cell migration (44) . TFPI has been shown to control migration of endothelial cells (45) .
Extracellular matrix bound TFPI through an interaction with tissue factor/VIIa complex localized on cancer cells has also been shown to facilitate cancer cell migration and adhesion (18).
SEL-1L, is the only member of the 7 gene panel shown to be downregulated in pancreatic tumors versus normal samples this study. SEL-1L is expressed abundantly only in the normal pancreas and is downregulated in pancreatic cancers. SEL-1L was first reported as a pancreas specific transcript but later found to be highly expressed in normal pancreas and present at very low levels in several other adult tissues (25, 46, 47) . SEL-1L loss of expression has been observed in 17% of pancreatic adenocarcinomas. Thus, SEL-1L represents a gene that shows a tissuerestricted pattern of expression with the only tissue demonstrating abundant expression being the pancreas. In addition, SEL-1L maps into a genomic interval for the insulin-dependent diabetes mellitus locus at chromosome 14q24.3-q31 but was later excluded as a candidate gene for diabetes (48) . Induced expression of SEL-1L in pancreatic cancer cells has been shown to decrease the clonogenity and anchorage-independent growth and it also delayed tumor growth in immunodeficient mice (49) . In addition SEL-1L has been reported to affect pancreatic cancer (52) . Interestingly WWTR1/TAZ, a transcription cofactor, was also found to regulate cell migration and invasion (13, 14) . WWTR1 has also been reported to be amplified in pancreatic cancer cell lines and in pancreatic cancer (53) . WWTR1 was found to play a role in the migration, invasion and tumorigenesis of breast cancer cells (13) . TGFBI has been reported to be overexpressed in colon and pancreatic cancer (16, 54) . TGFBI is an excreted extracellular matrix protein reported to play a role in cell-matrix regulation as well as cell migration in bone (55) . (56) . CDC42BPA, a protein kinase has also been implicated in tumor cell invasion (20) .
CDC42BPA in complex with a a leucine-rich adaptor protein LRAP35a, and MYO18A has been shown to play a crucial role in cell protusion and migration (57) . Therefore, all 7 genes in our panel have been closed linked functionally to the control of cell migration in cancer and potentially in the early stages of pancreatic tumorigenesis,
In addition, three of the seven genes identified as most differentially expressed, L1CAM, TGFBI
and CDC42BPA are mutated in the germline in genetic disorders including CRASH syndrome, Thiel Behnke corneal dystrophy and Crohn's disease respectively (58,59). Given that germline mutations underlying genetic disorders are very rare, the finding that our study identified 3/7
genes as being mutated in hereditary diseases indicates the functional significance of this migration pathway in early development, the deregulation of which could be of critical importance in pancreatic cancer initiation and progression.
In conclusion, we have taken a pathways approach to biomarker discovery by utilizing three different expression based platforms to identify chromosome 3p12 pathway genes differentially expressed between pancreatic tumor/normal samples which could serve as candidate biomarkers for the early detection of pancreatic cancer. Biomarker panels described herein will be further validated in larger case-control studies with the Early Detection Research Network (EDRN) of the National Cancer Institute. Additional candidates from the 7 gene list and associated IPA network members should also be investigated for their ability to improve performance of current panels as well. Future studies are also warranted to investigate the role of cell polarity and migration in the initiation of pancreatic cancer and the potential for biomarker discovery by a targeted pathway approach.
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